English, Article edition: A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs Sherine E. Gabriel; Douglas Coyle; Larry W. Moreland

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94321
Physical Description
  • article
Language
  • English

Edition details

Title
  • A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs
Author
  • Sherine E. Gabriel
  • Douglas Coyle
  • Larry W. Moreland
Physical Description
  • article
Notes
  • Rheumatoid arthritis is one of the most common chronic systemic inflammatory diseases, affecting approximately 1% of the adult population. Disease-modifying antirheumatic drugs (DMARDs) have been the mainstay of treatment for rheumatoid arthritis when combined with physical therapy and aspirin (acetylsalicylic acid) or nonsteroidal anti-inflammatory drugs. Recently, a number of new biological therapies have been introduced for the treatment of this condition and will have a major impact on the future management of this disabling disease. In this review, we summarise data on the efficacy and tolerability of the currently available DMARDs, including gold compounds, antimalarials, penicillamine, cytotoxic drugs (azathioprine and cyclophosphamide), sulfasalazine, methotrexate, leflunomide, cyclosporin, anti-tumour necrosis factor agents, combination therapy and apheresis. A literature review and quality assessment of economic evaluations of DMARDs is presented, illustrating that there has been a paucity of economic evaluations on these agents and showing the variable quality of those studies that are available. The manuscript also addresses the pharmacoeconomic implications of the new agents for rheumatoid arthritis; the need for formal long term economic evaluations in order to determine the cost effectiveness of these costly, but highly effective, new treatments is emphasised.
  • Antimalarials, Antirheumatics, Auranofin, Azathioprine, Cost analysis, Cyclophosphamide, Cyclosporin, Disease modifying antirheumatics, Etanercept, Gold, Infliximab, Leflunomide, Methotrexate, Penicillamine, Pharmacoeconomics, Rheumatoid arthritis, Sulfasalazine
  • RePEc:wkh:phecon:v:19:y:2001:i:7:p:715-728
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment